Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Psilocybin 25 mg Clear all
Recruiting Phase 1 Interventional

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

NCT06160284
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
25 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 2 Interventional

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

NCT06200155
View directory record Official record
Conditions
Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions
Psilocybin, Niacin
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 2 Interventional

Psilocybin on Brain Mechanisms of Motivation in OUD

NCT06810310
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin (high dose), psilocybin (low dose)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

NCT07610135
View directory record Official record
Conditions
Mood (Psychological Function), Well Being, Mood, Healthy
Interventions
Psilocybin, Pimavanserin, Inactive Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

NCT07818564
View directory record Official record
Conditions
Phase I
Interventions
Psilocybin (Usona Institute), Inactive Placebo (Usona Institute)
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Terminated Phase 1 Interventional

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

NCT05322954
View directory record Official record
Conditions
Methamphetamine Use Disorder, Substance-Related Disorders, Chemically-Induced Disorders, Substance Use Disorders, Stimulant-Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Not yet recruiting Phase 2 Interventional

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

NCT07296328
View directory record Official record
Conditions
Stuttering
Interventions
Psilocybin, Speech therapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 15, 2026, 9:13 AM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

NCT05554094
View directory record Official record
Conditions
PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

NCT07306364
View directory record Official record
Conditions
Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions
Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

NCT04424225
View directory record Official record
Conditions
Perception Disturbance, Visual Suppression, Psychedelic Experiences
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 1Phase 2 Interventional

Psilocybin-Assisted Therapy for Physician Well-Being and Burnout

NCT06814522
View directory record Official record
Conditions
Burnout, Burnout, Healthcare Workers
Interventions
Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Real-time Biofeedback
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin Therapy for Methamphetamine Use Disorder and HIV

NCT07756736
View directory record Official record
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

NCT05711940
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
62
States / cities
Gilbert, Arizona • Bellflower, California • Encino, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Active, not recruiting Phase 2 Interventional

Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder

NCT04410913
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
Drug
Lead sponsor
Keith Heinzerling
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2023 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 2 Interventional

Wellcome Leap Psilocybin for OUD

NCT06786325
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 15, 2026, 9:13 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

The Effects of Psilocybin on Social Connectedness

NCT07693153
View directory record Official record
Conditions
Loneliness, Grief
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Completed Phase 2 Interventional

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

NCT04661514
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 15, 2026, 9:13 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of Psilocybin for PTSD

NCT06407635
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin, Trauma-focused psychotherapy, Standard psychological support
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mindfulness-Assisted Psychedelic Therapy

NCT06233344
View directory record Official record
Conditions
Mental Health
Interventions
Psilocybin plus mindfulness training, Psilocybin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Active, not recruiting Phase 2 Interventional

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Recruiting Phase 2 Interventional

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

NCT06706232
View directory record Official record
Conditions
Bipolar II Disorder, Depression, Bipolar, Suicidality
Interventions
Psilocybin, Therapeutic Support
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

NCT04950608
View directory record Official record
Conditions
Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal
Interventions
Psilocybin, Psychotherapy
Drug · Behavioral
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Danvers, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 15, 2026, 9:13 AM EDT
Not yet recruiting Phase 2 Interventional

Psilocybin-Assisted Therapy

NCT07332143
View directory record Official record
Conditions
PTSD
Interventions
psilocybin, Supportive Therapy, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 15, 2026, 9:13 AM EDT